Business Segments · Operating Income (Loss)
Life Sciences — Operating Income (Loss)
Becton, Dickinson and Company Life Sciences — Operating Income (Loss) decreased by 41.5% to $93.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 75.7%, from $383.00M to $93.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026
Rolls up toOperating Income
How to read this metric
An increase reflects improved operational performance and profitability, while a decrease indicates margin pressure or operational challenges.
Detailed definition
This is the profit or loss generated by the Life Sciences segment after deducting all operating expenses, including COGS...
Peer comparison
Standard segment operating income metric used to compare profitability across business units in large-cap companies.
Metric ID:
bdx_segment_life_sciences_operating_income_lossHistorical Data
30 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $492.00M | $83.00M | $692.00M | $564.00M | $537.00M | $489.00M | $585.00M | $399.75M | $628.00M | $399.75M | $549.00M | $399.75M | $349.00M | $399.75M | $439.00M | $404.00M | $734.00M | $404.00M | $602.00M | $404.00M | $622.00M | $404.00M | $453.00M | $240.00M | $383.00M | $882.00M | $861.00M | $552.00M | $159.00M | $93.00M |
| QoQ Change | — | -83.1% | +733.7% | -18.5% | -4.8% | -8.9% | +19.6% | -31.7% | +57.1% | -36.3% | +37.3% | -27.2% | -12.7% | +14.5% | +9.8% | -8.0% | +81.7% | -45.0% | +49.0% | -32.9% | +54.0% | -35.0% | +12.1% | -47.0% | +59.6% | +130.3% | -2.4% | -35.9% | -71.2% | -41.5% |
| YoY Change | — | — | — | — | +9.1% | +489.2% | -15.5% | -42.2% | +11.3% | -29.1% | +2.2% | -25.6% | -28.6% | -18.3% | -25.0% | -30.9% | +16.9% | -35.7% | +9.7% | -26.4% | +78.2% | +15.8% | +3.2% | -45.3% | -47.8% | +46.5% | +38.4% | +21.9% | -64.9% | -75.7% |
Range$83.00M – $882.00M
CAGR-20.5%
Avg YoY Growth+8.9%
Median YoY Growth-16.9%
Current Streak4 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's life sciences — operating income (loss)?
- Becton, Dickinson and Company (BDX) reported life sciences — operating income (loss) of $93.00M in Q1 2026.
- How has Becton, Dickinson and Company's life sciences — operating income (loss) changed year-over-year?
- Becton, Dickinson and Company's life sciences — operating income (loss) decreased by 75.7% year-over-year, from $383.00M to $93.00M.
- What does life sciences — operating income (loss) mean?
- The total operating profit or loss for the Life Sciences segment.